All In Biotech

NDA 215910 · Sparc

Sezaby

Phenobarbital Sodium · Intravenous

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Nov 17, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

15 Phase 3, 2 recruiting

FAERS reports

416

405 serious, 62 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. If a decision is made for concomitant use of these drugs, limit dosages and durations to the minimum required, and follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.3)]. Dependence and Withdrawal Reactions After Use of SEZABY for a Longer Duration than Recommended The continued use...

What it is approved for

From the label in effect Oct 23, 2026.

SEZABY is indicated for the treatment of neonatal seizures in term and preterm infants. SEZABY is a barbiturate indicated for the treatment of neonatal seizures in term and preterm infants.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 17, 2022 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
  • SEZABY · PHENOBARBITAL SODIUM 100MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenobarbital" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure68
  • off label use60
  • drug ineffective58
  • epilepsy27
  • status epilepticus21
  • product use in unapproved indication19
  • pallor18
  • sepsis18
  • drug ineffective for unapproved indication17
  • condition aggravated16
  • confusional state15
  • drug resistance15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
20056
20071
20081
20092
20117
20126
201315
201410
201512
201619
201712
201850
201937
202019
202134
202237
202340
202441
202529
202630

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 609 on PubMed

Sponsor: Sparc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.